> top > projects > sentences > docs > PubMed:26935651 > annotations
sentences Home  

PubMed:26935651 JSONTXT 18 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-143 Sentence denotes Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder.
T1 0-143 Sentence denotes Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder.
TextSentencer_T2 144-216 Sentence denotes Depression is a disturbing psychiatric disease with unsatisfied therapy.
T2 144-216 Sentence denotes Depression is a disturbing psychiatric disease with unsatisfied therapy.
TextSentencer_T3 217-427 Sentence denotes Not all patients are sensitive to anti-depressants currently in use, side-effects are unavoidable during therapy, and the cases with effectiveness are always accompanied with delayed onset of clinical efficacy.
T3 217-427 Sentence denotes Not all patients are sensitive to anti-depressants currently in use, side-effects are unavoidable during therapy, and the cases with effectiveness are always accompanied with delayed onset of clinical efficacy.
TextSentencer_T4 428-521 Sentence denotes Delivering brain-derived neurotrophic factor (BDNF) to brain seems to be a promising therapy.
T4 428-521 Sentence denotes Delivering brain-derived neurotrophic factor (BDNF) to brain seems to be a promising therapy.
TextSentencer_T5 522-582 Sentence denotes However, a better approach to delivery is still rudimentary.
T5 522-582 Sentence denotes However, a better approach to delivery is still rudimentary.
TextSentencer_T6 583-758 Sentence denotes The purpose of our present work is to look for a rapid-onset and long-lasting therapeutic strategy for major depressive disorder (MDD) by effectively delivering BDNF to brain.
T6 583-758 Sentence denotes The purpose of our present work is to look for a rapid-onset and long-lasting therapeutic strategy for major depressive disorder (MDD) by effectively delivering BDNF to brain.
TextSentencer_T7 759-988 Sentence denotes BDNF, fused with cell-penetrating peptides (TAT and HA2), was packaged in adenovirus associated virus (AAV) to construct the BDNF-HA2TAT/AAV for intranasally delivering BDNF to central nervous system (CNS) via nose-brain pathway.
T7 759-988 Sentence denotes BDNF, fused with cell-penetrating peptides (TAT and HA2), was packaged in adenovirus associated virus (AAV) to construct the BDNF-HA2TAT/AAV for intranasally delivering BDNF to central nervous system (CNS) via nose-brain pathway.
TextSentencer_T8 989-1149 Sentence denotes Intranasal administration of BDNF-HA2TAT/AAV to normal mice displayed anti-depression effect in forced swimming test when the delivery lasted relatively longer.
T8 989-1149 Sentence denotes Intranasal administration of BDNF-HA2TAT/AAV to normal mice displayed anti-depression effect in forced swimming test when the delivery lasted relatively longer.
TextSentencer_T9 1150-1301 Sentence denotes The AAV applied to mice subjected to chronic mild stress (CMS) through intranasal administration for 10 days also alleviated depression-like behaviors.
T9 1150-1301 Sentence denotes The AAV applied to mice subjected to chronic mild stress (CMS) through intranasal administration for 10 days also alleviated depression-like behaviors.
TextSentencer_T10 1302-1413 Sentence denotes Western-blotting analysis revealed that BDNF-HA2TAT/AAV nasal administration enhanced hippocampal BDNF content.
T10 1302-1413 Sentence denotes Western-blotting analysis revealed that BDNF-HA2TAT/AAV nasal administration enhanced hippocampal BDNF content.
TextSentencer_T11 1414-1646 Sentence denotes These results indicate intranasal administration of constructed BDNF-HA2TAT/AAV exerts anti-depression effect in CMS mice by increasing hippocampal BDNF, suggesting that this strategy holds a promising therapeutic potential for MDD.
T11 1414-1646 Sentence denotes These results indicate intranasal administration of constructed BDNF-HA2TAT/AAV exerts anti-depression effect in CMS mice by increasing hippocampal BDNF, suggesting that this strategy holds a promising therapeutic potential for MDD.